Conditioning high-dose chemotherapy, infection prophylaxis in conjunction with cytopenia, and supportive care including standard oral care were administered according to institutional practice. Patients with multiple myeloma were conditioned with a single-dose intravenous Melphalan 140 mg/m² or 200 mg/m² on day -1, i.e., 24 hours before ASCT. Lymphoma patients were conditioned with either of the two high-dose chemotherapy regimens BEAC or BEAM. BEAC was administered according to the following figure: Day -6: carmustine 300 mg/m² and etoposide 100 mg/m²; Day -5 to -3: etoposide 200 mg/m², cytarabine 200 mg/m² and cyclophosphamide 35 mg/kg; Day -2: etoposide 100 mg/m², cytarabine 200 mg/m² and cyclophosphamide 35 mg/kg; Day -1: Recovery; Day 0: ASCT. The corresponding figure for BEAM was: Day -7: carmustine 300 mg/m²; Day -6 to -3: etoposide 200 mg/m² and cytarabine 400 mg/m²; Day -2: melphalan 140 mg/m²; Day -1: Recovery; Day 0: ASCT. All patients received autologous multipotent hematopoietic stem cells derived from peripheral-blood, collected after routine mobilization by means of chemotherapy and granulocyte-colony-stimulating factor (G-CSF; filgrastim), with a dose of $\geq 2 \times 10^6$ CD34+ cells/kg. Following ASCT, filgrastim or lipegfilgrastim was optionally administered according to the clinical routines established at each study site.